Device Cardiology/Vascular Diseases

Rivacor 7 Dr-T

Payments companies reported to CMS as associated with Rivacor 7 Dr-T. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$333Kassociated payments (2023-2025)
517clinicians with associated payments
1company reporting

By year

2023 $268K
2024 $55K
2025 $9,073

Payments reported as associated with Rivacor 7 Dr-T, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Clinical Cardiac Electrophysiology $254K
Cardiovascular Disease $34K
Advanced Heart Failure and Transplant Cardiology $21K
Internal Medicine $3,831
Interventional Cardiology $3,640
Physician Assistant $3,021

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Rivacor 7 Dr-T

These are the largest totals companies reported as associated with Rivacor 7 Dr-T. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Gaurav Upadhyay Chicago, IL Clinical Cardiac Electrophysiology $125,130.87
Chad Bonhomme Westfield, IN Clinical Cardiac Electrophysiology $58,090.00
Marrick Kukin New York, NY Cardiovascular Disease $15,115.00
James Heywood La Jolla, CA Advanced Heart Failure and Transplant Cardiology $12,400.00
Emil Missov Greenville, NC Advanced Heart Failure and Transplant Cardiology $7,200.00
Emad Aziz Newark, NJ Clinical Cardiac Electrophysiology $6,600.00
Roderick Tung Chicago, IL Clinical Cardiac Electrophysiology $2,727.74
Antonio Moretta Sarasota, FL Clinical Cardiac Electrophysiology $2,142.78
Kalyanam Shivkumar Los Angeles, CA Cardiovascular Disease $1,909.72
Gregory Harris Greenville, NC Clinical Cardiac Electrophysiology $1,685.68

Prescribed Rivacor 7 Dr-T?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.